Introduction {#Sec1}
============

Idiopathic nephrotic syndrome (INS) is one of the most common glomerular diseases in children and adults, the central event being podocyte injury. INS is a heterogeneous disease and treatment is largely empirical and unsuccessful, with steroids as the initial mainstay of therapy. Up to 90% of children with INS have some response to steroids and are labelled as steroid-"sensitive" (SSNS), and the rest as steroid-"resistant" (SRNS, most can also be described by histology as focal segmental glomerulosclerosis, FSGS), with single gene mutations underlying a large proportion of the latter group \[[@CR1], [@CR2]\]. The burden of morbidity is enormous, both to patients with lifelong chronic disease, and to health services, particularly managing dialysis and transplantation.

The current protocol for the management of INS is treatment with high-dose steroids. Of resistant patients, only 30% will respond over time to powerful second- and third-line immunosuppression; the rest suffer major long-term morbidity and renal failure requiring dialysis/transplantation. Up to 50% develop rapid recurrence post-transplantation, with eventual graft loss, despite highly intensive treatments.

Advances in genetics, both by identification of single gene mutations and in our ability to rapidly screen patients, have begun to allow practical steps towards the mechanistic stratification of disease and therefore of predicting disease recurrence in those patients. A patient identified as having a monogenic cause of their NS is far less likely to suffer recurrence of disease post-transplantation, although the absolute risk remains undefined. The challenge now is to enhance our understanding of which patients suffer recurrence, using our expanding knowledge of disease mechanisms based on podocyte biology.

Predictions based on pre-transplant clinical categorisation {#Sec2}
===========================================================

To date, different studies have identified different clinical features with relatively weak correlations with post-transplant recurrence. Features such as age at onset, race, live related donation, histological severity etc. have been weakly linked in some studies with an enhanced risk \[[@CR3]--[@CR6]\]. Odorico et al. retrospectively evaluated the effects of bilateral native nephrectomy before transplant in patients with recurrent disease post-transplant \[[@CR7]\]. The incidence of recurrence was 40% in the nephrectomised patients as opposed to 16.1% among non-nephrectomised patients, although other small studies have not found a significant difference \[[@CR8]\]. As a potential explanation, it was proposed that native kidneys act to absorb permeability factors, although I speculate that it is a reflection of the more aggressive circulating factor disease (CFD, see below).

The most consistent features reported in the literature over many years have been rapid progression to established renal failure (ERF), a lower age at diagnosis, and greater degrees of proteinuria in the recurrent groups \[[@CR3], [@CR6], [@CR8], [@CR9]\]. A summary of key findings regarding risk factors predisposing to recurrence, from the main studies in the literature, is provided in Table [1](#Tab1){ref-type="table"}.Table 1Summary and comparison of clinical features in patients with and without recurrence of focal segmental glomerulosclerosis (FSGS) post-transplantationAge groupNumber of patientsNumber with recurrence vs number with no recurrenceAge at diagnosisAge at transplantationRace: percentage whitePercentage maleSerum albumin at diagnosis (g/dL)Genetic diagnosisUrine protein at diagnosisPre-transplant proteinuriaTime to ERFeGFR at diagnosisMesangial proliferation (native Bx)Bilateral nephrectomyLiving donationReferencePaediatric2915 vs 14NSNSNS3.9 vs 6.2 years (*p* \< 0.05)\[[@CR9]\]Adult225 vs 1739 vs 48 years20 vs 76 (*p* = 0.02)2.63 vs 3.45 (*p* \< 0.05)7.0 vs 2.5 g/day (*p* \< 0.05)3.1 vs 11.9 years (*p* \< 0.05)3 vs 0 (*p* \< 0.05)\[[@CR10]\]Paediatric and adult255 vs 2012.5 vs 25.9 years (*p* = 0.02)3.78 vs 5.68 years (NS)\[[@CR11]\]Paediatric and adult7225 vs 53NS67 vs 73 (NS)49 vs 101 months (*p* = 0.022)52% vs 45% (NS)\[[@CR12]\]Paediatric166 vs 107.2 vs 6.1 years (NS)11.8 vs 13.6 years (NS)67 vs 90 (NS)41 vs 77 months (*p* = 0.045)29% vs 40% (NS)71% vs 70% (NS)\[[@CR13]\]Paediatric13227 vs 10590 vs 59 (*p* = 0.027)78 vs 48 (NS)\[[@CR5]\]Paediatric and adult5913 vs 468.0 vs 9.1 years (children); 25.7 vs 28.4 years (adults)50% recurrence in \<15 years, 11% in adolescents/adults3.5 vs 5.0 years (children, NS); 5.1 vs 4.8 years (adults, NS)\[[@CR13]\]Adult9428 vs 6623 vs 29 years32 vs 38 (NS)57 vs 5320 vs 31 g/L (*p* \< 0.01)11.7 vs 5.9 g/day (*p* \< 0.01)4.9 vs 3.7 years (NS)1 vs 5 (NS)14% vs 22% (NS)\[[@CR6]\]Adult3014 vs 1631 vs 45 years (*p* \< 0.03)64 vs 8113.4 vs 6.2 g/D (peak proteinuria, *p* \< 0.01)0% vs 70% (*p* \< 0.01)4.5 vs 5.5 years (NS)69% vs 36% (*p* = 0.07)24% vs 18% (NS)\[[@CR3]\]Paediatric229 vs 136.7 vs 5.3 years56 vs 85 (NS)9.0 vs 4.9 g/day (NS)3.1 vs 6.1 years (*p* \< 0.05)44% vs 50% (NS)44% vs 62% (NS)\[[@CR15]\]Paediatric15057 vs 9167 vs 82 (NS)50 vs 72 (NS)0% vs 27%4.0 vs 3.0 years (NS)15% vs 5% (*p* = 0.05)\[[@CR16]\]Paediatric286 vs 22\<6 vs \>6 years (*p* \< 0.05)NSNSNS\[[@CR4]\]Paediatric138 vs 56.5 vs 2.9 years (NS)6.9 vs 11.1 years (NS)63 vs 100 (NS)13.6 vs 1.9 g/D (peak proteinuria, NS)13.2 vs 43.6 months (*p* \< 0.05)\[[@CR8]\]All data fields compare patients with recurrence with patients with no recurrence*NS* non-significant, *ERF* established renal failure, *eGFR* estimated glomerular filtration rate

Initial steroid sensitivity {#Sec3}
===========================

We have recently reported by far the strongest predictive clinical feature of CFD to date, upon retrospective study of 150 grafts in FSGS children, from three large centres \[[@CR16]\]. We hypothesised that the circulating factor is highly likely to be related to immune activation, and therefore if a patient responds to steroids early in the course of their disease (initial steroid sensitivity), this is proxy evidence for the presence of a circulating factor. Therefore, they are more likely to suffer from recurrence post-transplantation. Our study confirmed this hypothesis, showing that of 150 patients, 57 developed recurrence, and 26 out of 28 with initial steroid sensitivity suffered recurrence (*p* \< 0.001, odds ratio 30). In contrast, none of the patients in the genetic or family history group suffered recurrence. This still leaves a clinically non-predictable group, those with primary steroid resistance and no genetic diagnosis according to the current screening. This group has an approximately 50% risk of recurrence, as shown by this study, and also according to our national screening study, which was far more complete in the genetic screening of the cohort \[[@CR1]\].

Secondary FSGS {#Sec4}
==============

Similar to genetic FSGS, FSGS secondary to other causes does not recur after kidney transplantation if the causes no longer exist; some of the reported FSGS cases without recurrence may in fact have been secondary FSGS. FSGS is an unspecific histological finding that is seen in many conditions of different aetiologies. Apart from genetic causes, which are considered to be primary, FSGS lesions can also be found as a secondary consequence of glomerular hypertrophy or hyperfiltration, toxins, obesity, HIV-associated nephropathy or scarring caused by previous injury (e.g., vasculitis, lupus).

Rudnicki reported that patients who present with proteinuria, but without oedema did not experience recurrence \[[@CR17]\]. These patients would normally be categorised as having primary FSGS, as no underlying secondary cause was discovered. Therefore, the histological diagnosis of FSGS itself does not mean that the disease could recur after kidney transplantation.

The careful application of clinical criteria to separate disease categories is now beginning to clarify some of the risk features. In a study of 94 transplanted FSGS patients with a mean age of 37, Maas et al. separated patients into genetic (18 patients), secondary (10 patients) and idiopathic FSGS (66 patients). Only patients in the latter category developed recurrence, and the only independent predictor was serum albumin at diagnosis \[[@CR6]\].

Recurrence risk after re-transplantation {#Sec5}
========================================

There is strong evidence that if a patient suffers a recurrence in the first allograft, then the second and subsequent transplants will have an even higher risk of recurrence compared with a first graft. The rate of recurrence is up to 80%, particularly if the first graft was lost early. Most studies have consistently quoted rates as high as 80% in the second transplant and \>90% in the third and subsequent transplants \[[@CR5], [@CR18]\].

There is, however, some indication that if the recurrence in the first graft was relatively mild (i.e., the kidney was not lost rapidly), then subsequent grafts also follow the same pattern of recurrence with relatively prolonged function (ranging between 4 and 10.5 years in one study) \[[@CR19]\].

Synthesis of results from literature series {#Sec6}
===========================================

Overall, by reviewing all case series published, a certain pattern emerges. The first is from our own study, which shows by far the strongest predictor to date of recurrence, which is initial steroid sensitivity (alternatively termed secondary steroid resistance) \[[@CR16]\]. This is further confirmed in our follow-up profile of a national cohort of SRNS patients, where 4 out of 5 secondary steroid-resistant patients (80%) developed recurrence, and 0 out of 25 patients with secondary resistance had a mutation in any of the 53 SRNS genes tested \[[@CR1]\].

The second interesting trend is that patients with recurrence tend to have a lower serum albumin at presentation, greater proteinuria, and faster time to dialysis from presentation. This indicates more aggressive ongoing glomerular damage in (progressive) CFD, and could be used as an additional clinical clue early in the disease process. This would also explain the finding of a higher rate of bilateral nephrectomies in those who subsequently develop recurrence, as those with more aggressive disease are likely to be put forward for nephrectomy pre-transplant, to recover serum albumin levels.

Whole exome sequencing was performed on a UK national cohort of children with SRNS, and patients stratified according to the pattern of steroid response, followed by genetic diagnosis. Recurrence risk was highest in those with secondary steroid resistance, and lowest in those with a gene mutation underlying their SRNS.

With regard to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the mean age at onset of NS and mean age at onset of end-stage renal failure (ESRF) were compared and the only significant difference (\#) was noted for mean time to ESRF between primary + presumed monogenic and primary + presumed non-monogenic/unknown and secondary SRNS, with *p* value 0.0311 (two-tailed unpaired*t* test).

Advances in biological understanding {#Sec7}
====================================

The target cell of NS is the glomerular podocyte, and podocyte biology research has exploded in recent years. Landmark genetic and biological studies over the last 15 years have advanced glomerular biology at a remarkable pace, pointing compellingly to the podocyte as a uniquely functioning cell within the body, let alone the glomerulus, with pathways centring on the actin cytoskeleton and integrin signalling as tightly regulated nodes controlling the healthy function of the filtration barrier \[[@CR20]\]. Idiopathic NS (INS) is an exemplar of primary glomerular disease. It is a rare disease, heterogeneous in cause, and therefore an accurate prediction of response post-transplant depends on stratification of disease at a mechanistic, rather than at an observational level.Monogenic disease. Currently, there are single gene defects causing NS reported for 55 different genes \[[@CR1], [@CR21], [@CR22]\]. Given the growing evidence that a monogenic cause for SRNS does not predispose to post-transplant recurrence, it is a crucial part of the management pathway to screen for known genetic mutations. Current availability of gene panels allows for this to be achieved at speed and relatively low cost compared with previous Sanger technologies (e.g., Bristol clinical SRNS gene panel, [www.nbt.nhs.uk/severn-pathology/pathology-services/bristol-genetics-laboratory-bgl](http://www.nbt.nhs.uk/severn-pathology/pathology-services/bristol-genetics-laboratory-bgl)) \[[@CR23]\]."Circulating factor disease". Recurrent disease post-transplant is the archetypal CFD, and is almost certainly linked to immune activation, and possibly a circulating factor(s) released by immune cells themselves. We currently have no reliable biomarkers to detect CFD, either pre- or post-transplant, although many have suggested potential circulating factors that would fit the biological scenario. These include suPAR \[[@CR24]\], hemopexin, TNF-α \[[@CR25]\], galactose \[[@CR26]\], etc. To date, none has consistently been shown to be active in post-transplant disease.Unknown. There is currently limited evidence either way to support whether there is a cohort of patients with INS with a different disease mechanism to 1 or 2 above. The discovery of biomarkers for CFD (see below), alongside complete genetic testing significantly clarify if such a unique phenotypic cohort exists, or what proportion of patients can be classified into the first two groups.

Recurrence in NS caused by a monogenic disorder {#Sec8}
===============================================

To date, there has been little definitive evidence that patients with a genetic mutation causing SRNS will develop post-transplant recurrence of nephrotic range proteinuria. There are a few reports, predominantly with *NPHS2* variants, that suggest that this might occur. The risk of post-transplant recurrence in patients with podocin mutations may be rather confusing as single heterozygous mutations were included in some studies \[[@CR27]\].

True homozygous or compound heterozygous mutations in podocin have been found in a few patients with post-transplant NS recurrence ranging from as soon as 7 days to 10 years post-transplant \[[@CR27]--[@CR34]\].

Similarly, post-transplant nephrotic-range proteinuria was noted in a patient with Frasier syndrome and a mutation in *WT1* \[[@CR35]\]. FSGS recurrence has also been suggested in a patient with *ACTN4*, although the biopsy findings were non-specific \[[@CR36]\].

As no anti-podocin antibodies have been detected in the tested *NPHS2* patients, even those with truncating mutations \[[@CR27], [@CR29], [@CR30]\], the pathomechanism resulting in the disease recurrence is yet to be found. The pattern of proteinuria clearly needs to be carefully taken into account, as there are different potential causes in any transplant, and secondary morbidities should be considered.

Re-analysis of SRNS causal variants {#Sec9}
===================================

It is important that certain additional caveats are considered here, in particular, whether the variants reported as "causative" are truly so. A consistent issue in any gene test for mutation reporting is whether or not any rare variant is pathogenic, and there is no single definitive test. The proof lies predominantly in the frequency of that variant in the population (which also varies according to ethnicity), in addition to its frequency in the disease population, added to in silico corroborations such as conservation across species and deleterious functional predictions, and ultimately biological testing. Our ability to define variant frequencies in populations has expanded exponentially in recent years, in particular, with the development of large-scale reference datasets, such as the Exome Aggregation Consortium (ExAC). Interestingly, analysis of over 60,000 human exomes revealed that 72% of genes with predicted protein-truncating variants had no known human disease phenotype \[[@CR37]\]. In addition, the average individual has 54 variants previously classified as causing a rare disorder, suggesting that these might have been incorrectly classified. When analysed, only 9 out of 192 variants previously classified as causing a Mendelian disease were supported as genuine by this new evidence of population variant frequency.

Overall, for SRNS, this suggests that almost all historical reports of causal variants need to be reassessed against current reference datasets, to filter out those that are no longer deemed causative. Equally, this means that historical reports of recurrence in "genetic" SRNS should be constantly reanalysed against this new information.

A particular misdiagnosis in the past is of pathogenicity of the R229Q variant in podocin, which is present in 4--5% of the general population, is associated with microalbuminuria \[[@CR38]\], and is shown in biological models to have deleterious functional consequences \[[@CR39]\]. More recently, however, it was elegantly shown that this variant only causes human SRNS when in combination with a pathogenic/rare variant on exon 8 of the second *NPHS2* allele \[[@CR40]\]. Therefore, any recurrence seen in a patient with R229Q and a different *NPHS2* rare variant should be considered non-genetic unless an alternative pathogenic variant is identified.

A true genetic cause of recurrent CFD would likely involve a mutation in a gene related to the immune system, or a cognate receptor on the podocyte. It is interesting to note that we are not aware of any reports to date of familial recurrence (more than one member) of SRNS post-transplant, and advise caution in interpreting recurrence in cases with a structural podocyte defect.

Which patients with SRNS should be offered living-related donation? {#Sec10}
===================================================================

It has previously been shown in some studies that living-related donation (LD) is a risk factor for recurrence compared with cadaveric donation (CD). This is not consistent, and data from three large registries (NAPRTCS \[[@CR41]\], USRDS \[[@CR42]\] and RADR \[[@CR43]\]) suggest no difference in recurrence rates between LD and CD recipients. However, the Australian and New Zealand Dialysis and Transplant Registry study did find that LD transplantation is an independent risk factor for recurrence (*p* = 0.02) \[[@CR44]\]. We can speculate that in the studies showing a higher risk of LD, this is likely to represent a selection bias. The LD cohort historically will have screened out a proportion of genetic/familial donors, and is therefore enriched for recipients with CFD. Another factor may be the more rapid onset of renal failure in genetic vs non-genetic patients, meaning that genetic patients are more likely to be younger at transplantation, and therefore less suitable for an offer of an LD (adult) kidney.

To update advice on LD versus CD donation, we have divided the patients into those with an identified mutation, and those without. Individuals with identified autosomal dominant causality (heterozygous mutations) may present with variable phenotype/penetrance, including adult onset of NS; thus, living-related donors in this case may increase the risk of NS both in the recipient of the kidney and the donor, and should not be used.

In general, if a mutation is found in an autosomal recessive gene, a heterozygous carrier (parent) would be accepted to donate a kidney, with a negligible risk of recurrence. This excludes cases of Afro-Caribbean donors carrying the *APOL1* risk variant, where the risk of long-term renal decline is greater.

In cases in which a mutation has not been identified, our current practice is to strongly advise against living donation, unless the family is willing to proceed knowing the (high) risks. According to our recent national study \[[@CR1]\], and supported by our retrospective review \[[@CR16]\], the rate of recurrence in patients testing negative by a genetic screening panel \[[@CR23]\] or exome screening is around 50%.

In cases in which there is a family history suggestive of a dominant mutation (with no responsible gene identified), it is clear that living donation from that side of the family should be avoided. Even if the potential donor does not have evident disease, the potential for incomplete penetrance remains.

Circulating factor biomarkers {#Sec11}
=============================

Circulating factor disease is a very significant subset of idiopathic nephrotic syndrome as a whole, and early post-transplant recurrence is an archetypal manifestation of CFD. Therefore, finding specific biomarkers in peripheral blood that identify CFD would be a major breakthrough in both early diagnosis and therefore targeted management, in addition to prediction of recurrence risk.

Savin et al. developed the original "permeability factor" assay, based on the swelling of ex vivo rat glomeruli in response to exposure to FSGS plasma \[[@CR45]\]. Using this assay, a subsequent study reported 11 out of 13 children who tested positive for the permeability factor versus 4 out of 12 with negative results had a recurrence of FSGS after renal transplantation \[[@CR9]\]. The odds ratio in the former group was 10.99 (with a 95% confidence interval of 1.6--75.5). However, using a different measure of glomerular permeability, another group failed to find any predictive value of pre-transplant measurements on the risk of recurrence \[[@CR46]\].

Other groups have reported various putative circulating factors over many years, which have been reviewed elsewhere \[[@CR47], [@CR48]\], with no definitive candidate yet established.

Our approach over several years has been to utilise human podocytes in vitro and expose them to plasma exchange fluid taken from patients with early recurrence. This would mimic the disease situation of a circulating factor damaging podocytes in vivo, and the key is to find a damage pathway in the podocyte that is consistent in response to disease plasma. To date, we have demonstrated changes in the localisation of slit diaphragm proteins nephrin, podocin and CD2AP \[[@CR49]\], in addition to enhanced phosphorylation of the actin regulating protein VASP \[[@CR50]\], and functionally we can show an increase in podocyte motility. These responses are consistent when using plasma exchange fluid, although our follow-up testing of peripheral blood samples from patients at various stages of disease suggests that VASP phosphorylation may be less consistent as a biomarker (unpublished data). This could suggest different factors in pre-transplant disease, with differing downstream effects, although a more prosaic difficulty is obtaining fresh samples adequately stored. A key practical message in this type of clinical research is that aliquoting and early freezing of these valuable samples is as important a step in the experimental procedure as any other.

With these issues in mind, in the UK, we have undertaken a project termed the National Unified Renal Translational Research Enterprise (NURTuRE), in which samples will be collected according to strict protocols by dedicated research nursing staff, and stored centrally. This, and initiatives such as NEPTUNE in the USA \[[@CR51]\], will be important resources in the future for high-quality biomarker studies in INS.

What proportion of patients with SRNS have circulating factor disease? {#Sec12}
======================================================================

We estimate, based on children with a recurrence rate in INS post-transplant of 40--60% (the archetypal CF disease), and a separate 20--30% rate of monogenic/familial disease in this cohort, there is a potential 10--40% "unknown mechanism" group remaining to be defined.

Can we speculate what proportion of children overall with SRNS, and what proportion with primary SRNS in the "genetic testing negative" group have a CFD (and therefore are at risk of recurrence)? In our national cohort, tested by exome sequencing, the latter subset comprises 69% of all SRNS patients, and 48% of those transplanted from this subset suffered recurrence (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1]\]. This implies that at least 48% of that subset has CFD, and potentially more, although those who did not suffer recurrence would have a different or milder disease phenotype. For the whole cohort, if we add that number to the secondary SRNS subgroup, that yields 79 out of 181 patients with presumed CFD, i.e. 43.6% of the total cohort. We know a separate 26.5% have a definite monogenic cause, leaving 29.9% overall unknown. Some of those have an undiscovered genetic mutation, and the rest could have CFD or another as yet unknown mechanism.Fig. 1A genetic and clinical screening-based algorithm for predicting recurrence risk in steroid-resistant nephrotic syndrome (SRNS; from Bierzynska et al. \[[@CR1]\], used with permission), *NS* nephrotic syndrome, *ESRF* end stage renal failure

Conclusion {#Sec13}
==========

Understanding and clinical identification of the mechanistic subgroups of NS lead to far better ability to predict outcomes, including recurrence risk. The group that suffer recurrence has a CFD that appears from the larger studies to date to be distinct from genetic NS. No familial cases of post-transplant recurrence have yet been reported.

With careful consideration of genetics, clinical features, and in future molecular biomarkers, we are getting far closer to accurate prognostication of the recurrence risk, and more targeted treatments to minimise that risk.

This article is part of the topical collection "What's New in Renal Transplantation?"
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